The role of triacylglycerols and repurposing DGAT1 inhibitors for the treatment of Mycobacterium tuberculosis

Alice R Moorey; Gurdyal S Besra

doi:10.1016/j.tcsw.2022.100083

The role of triacylglycerols and repurposing DGAT1 inhibitors for the treatment of Mycobacterium tuberculosis

Cell Surf. 2022 Oct 15:8:100083. doi: 10.1016/j.tcsw.2022.100083. eCollection 2022 Dec.

Authors

Alice R Moorey¹, Gurdyal S Besra¹

Affiliation

¹ Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Birmingham B15 2TT, UK.

Abstract

Latent tuberculosis poses a significant threat to global health through the incubation of undiagnosed infections within the community, and through its tolerance to antibiotics. This Special Features article explores the mechanisms by which the dormant Mycobacterium tuberculosis pathogen can store energy in the form of lipid inclusion bodies and triacylglycerols, which may be key in the development of novel therapeutics to treat TB.

Keywords: Mycobacterium tuberculosis; Tgs; Triacylglycerols.

Publication types

Review

Abstract

Publication types

Grants and funding